GABA-glutamate Interactions and Psychosis

Yale University

Status and phase

Completed

Phase 1

Conditions

Cognitive Dysfunction

Treatments

Drug: iomazenil

Study type

Interventional

Funder types

Other

Identifiers

NCT00611572

0508000517

Details and patient eligibility

About

This study investigates the interactions between NMDA (N-Methyl-D-aspartic acid) antagonism and GABA (gamma-aminobutyric acid) system as it relates to cognitive function assessed by ERPs (event-related potentials) in healthy volunteers.

Enrollment

23 patients

Sex

All

Ages

21 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Ages of 21-45 years from all ethnic backgrounds.
Male or female.
Written informed consent.

Exclusion criteria

DSM-IV diagnosis for a psychotic, depressive or anxiety disorder.
A history of significant medical/neurological disease such as cardiac, thyroid, renal, hepatic abnormality, seizure disorder. Unstable medical condition based on EKG, vital signs, physical examination and laboratory work-up (CBC with differential, SMA-7, LFTs, TFTs, UA, Utox).
History of abnormal EEG.
History of severe allergies or multiple adverse drug reactions.
Any medication that could interfere with either the safety of the study and/or the outcome measures.
Any other conditions which in the opinion of the investigator would preclude participation in the study.
History of major psychiatric disorder in first degree relatives.
Current substance abuse/dependency determined by urine toxicology.
Treatment with medications with CNS effects.
Treatment with benzodiazepines within one week prior to testing.
Current treatment with medications with psychotropic effects.
Education < 10th grade.
IQ < 70, MR.
Non-English speaking.